CompletedNot Applicable

Pistacia Lentiscus Oil Nasal Drops for Preventing Recurrence of Chronic Rhinosinusitis

Italy100 participantsStarted 2024-03-04

Plain-language summary

This randomized, double-blind, placebo-controlled clinical trial evaluated the safety and efficacy of nasal drops containing Pistacia lentiscus oil in preventing recurrence of chronic rhinosinusitis. Adult patients with chronic rhinosinusitis were randomized 1:1 to receive either isotonic saline wash plus Pistacia lentiscus oil drops or isotonic saline wash plus placebo, for a total treatment duration of 12 months. The primary outcome was change in Sino-Nasal Outcome Test-22 (SNOT-22) scores, while secondary outcomes included ciliary motility, nasal secretion, biofilm presence, cytological changes, adverse events, and safety/tolerability.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Clinical diagnosis of chronic rhinosinusitis * Nasal polypoid score ≤1 * ≥4 episodes of recurrence per year * SNOT-22 score ≥10 Willingness and ability to provide written informed consent Exclusion Criteria: * Nasal polypoid score \>2 * \<4 episodes of recurrence per year * SNOT-22 score \<10 * Known immune disorders * Neoplastic disorders * Neurological disorders * Psychiatric disorders * Inability to undergo treatment * Refusal or inability to provide informed consent

What they're measuring

Change in Sino-Nasal Outcome Test-22 (SNOT-22) score

Timeframe: Baseline, 1 month, and 1 year

Trial details

NCT IDNCT07198607

SponsorLiaquat University of Medical & Health Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-18

View on ClinicalTrials.gov More Chronic Rhinosinusitis Without Nasal Polyps trials